Results 221 to 230 of about 27,891 (313)

The Risk of GLP‐1 Receptor Agonist (GLP‐1 RA) Exposure in Early Pregnancy. A Call to Action: Quantifying the Impact on Pregnancy Outcomes in the United Kingdom

Diabetes, Obesity and Metabolism, EarlyView.
Michael Stedman, Pensee Wu, Ian Halsall, Nadia Chaudhury, Barbara McGowan, Martin B. Whyte, Akheel Syed, Adrian Heald   +7 more
wiley   +1 more source

Clinical, Radiographic, and Histopathologic Features of Human Perigraftitis

Journal of Esthetic and Restorative Dentistry, EarlyView.
ABSTRACT Objective Perigraftitis is a biologic complication associated with dental implants placed in grafted bone, distinct from peri‐implant mucositis and peri‐implantitis. This report further characterizes its clinical, radiographic, and histopathologic features.
Jonathan H. Do, Charles M. Cobb, John T. Shen   +2 more
wiley   +1 more source

A Pharmacovigilance Analysis of Ocular Adverse Events Associated with GLP-1 Receptor Agonists. [PDF]

J Clin Med
Virk A, Allison K.
europepmc   +1 more source

Multidisciplinary Therapy to Target Obesity and Its Complications in Adult Population: A Narrative Review

Obesity Reviews, EarlyView.
ABSTRACT Obesity as a chronic and multifactorial disease requires a multidisciplinary team acting together in a holistic multitarget intervention. Multidisciplinary therapy targeting obesity and its complications includes physical exercise, nutritional, and behavior counseling.
Ana Raimunda Dâmaso, Flávia Campos Corgosinho, Deborah Cristina Landi Masquio, Nayra Figueiredo, Fabiana Kattah, Cintia Cercato, Lian Tock, Raquel Munhoz da Silveira Campos   +7 more
wiley   +1 more source

Evaluating Semaglutide's Protection in H/R - Injured AC16 Cardiomyocytes: Oxidative Stress, Inflammation, Apoptosis, and Autophagy Insights. [PDF]

Int J Gen Med
Li L, Jin L, Wang J.
europepmc   +1 more source

Efficacy of Weight‐Lowering Agents on Fat Distribution: A Systematic Review and Network Meta‐Analysis of Randomized Controlled Trials

Obesity Reviews, EarlyView.
ABSTRACT Background Pharmacotherapy offers a potential solution for individuals with overweight and obesity to decrease their body weight. However, there is limited knowledge of the effects of antiobesity agents on the distribution of body fat. Methods The PubMed, Embase, and Cochrane Library databases were reviewed for randomized controlled trials ...
Xiuqi Qiao, Weihao Wang, Jiaming Cao, Lixin Guo, Qi Pan   +4 more
wiley   +1 more source

Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial. [PDF]

Nat Med
Heymsfield SB, Aronne LJ, Montgomery P, Klickstein LB, Coleman LA, Dole K, Mindeholm L, Spruill S, Li X, Attie KM, BELIEVE trial investigators.   +10 more
europepmc   +1 more source

A Systematic Review and Meta‐Analysis of Semaglutide Effects on Adipose Tissue and Emerging Effects on Brain and Cognition

Obesity Reviews, EarlyView.
ABSTRACT Background In 2023 and 2024, research into semaglutide (SEMA), an antiobesity and antidiabetic medication, indicated potential benefits beyond its approved uses, particularly in preventing Alzheimer's disease (AD). This highlights the link between obesity and AD development.
Amene Saghazadeh, Mahsa Dolatshahi, Soheil Mohammadi, Sara Hosseinzadeh Kassani, Mahshid Naghashzadeh, Joseph E. Ippolito, Claude B. Sirlin, Bettina Mittendorfer, Matthew R. Brier, Suzanne E. Schindler, John C. Morris, Danny Mou, Hani Charles Soudah, Tammie L. S. Benzinger, Cyrus A. Raji   +14 more
wiley   +1 more source

Semaglutide Plus Low-Dose Metformin Combination Therapy for the Treatment of Obesity and Prediabetes in a Woman with Partial Deletion of the X Chromosome Long Arm. [PDF]

Reports (MDPI)
Marzolla V, Gorini S, Caprio M, Infante M.   +3 more
europepmc   +1 more source